Literature DB >> 17105855

Farber's disease without central nervous system involvement: bone-marrow transplantation provides a promising new approach.

K Ehlert, J Roth, M Frosch, N Fehse, N Zander, J Vormoor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17105855      PMCID： PMC1798467          DOI： 10.1136/ard.2005.048322

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  5 in total

1.  Successful hematopoietic stem cell transplantation in Farber disease.

Authors:  Josef Vormoor; Karoline Ehlert; Andreas H Groll; Hans-Georg Koch; Michael Frosch; Johannes Roth
Journal:  J Pediatr       Date:  2004-01       Impact factor: 4.406

2.  The role of ceramide in receptor- and stress-induced apoptosis studied in acidic ceramidase-deficient Farber disease cells.

Authors:  C Burek; J Roth; H G Koch; K Harzer; M Los; K Schulze-Osthoff
Journal:  Oncogene       Date:  2001-10-04       Impact factor: 9.867

3.  Bone marrow transplantation for infantile ceramidase deficiency (Farber disease).

Authors:  A M Yeager; K A Uhas; C D Coles; P C Davis; W L Krause; H W Moser
Journal:  Bone Marrow Transplant       Date:  2000-08       Impact factor: 5.483

4.  A case of lipogranulomatosis Farber: some clinical and ultrastructural aspects.

Authors:  U Burck; H W Moser; H H Goebel; R Grüttner; K R Held
Journal:  Eur J Pediatr       Date:  1985-01       Impact factor: 3.183

5.  Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome.

Authors:  C Peters; M Balthazor; E G Shapiro; R J King; C Kollman; J D Hegland; J Henslee-Downey; M E Trigg; M J Cowan; J Sanders; N Bunin; H Weinstein; C Lenarsky; P Falk; R Harris; T Bowen; T E Williams; G H Grayson; P Warkentin; L Sender; V A Cool; M Crittenden; S Packman; P Kaplan; L A Lockman; J Anderson; W Krivit; K Dusenbery; J Wagner
Journal:  Blood       Date:  1996-06-01       Impact factor: 22.113
  5 in total
  4 in total

1.  Autologous transplantation of lentivector/acid ceramidase-transduced hematopoietic cells in nonhuman primates.

Authors:  Jagdeep S Walia; Anton Neschadim; Orlay Lopez-Perez; Abdulfatah Alayoubi; Xin Fan; Stéphane Carpentier; Melissa Madden; Chyan-Jang Lee; Fred Cheung; David A Jaffray; Thierry Levade; J Andrea McCart; Jeffrey A Medin
Journal:  Hum Gene Ther       Date:  2011-03-25       Impact factor: 5.695

2.  In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease.

Authors:  Shobha Ramsubir; Takahiro Nonaka; Carmen Bedia Girbés; Stéphane Carpentier; Thierry Levade; Jeffrey A Medin
Journal:  Mol Genet Metab       Date:  2008-09-20       Impact factor: 4.797

3.  Systemic ceramide accumulation leads to severe and varied pathological consequences.

Authors:  Abdulfatah M Alayoubi; James C M Wang; Bryan C Y Au; Stéphane Carpentier; Virginie Garcia; Shaalee Dworski; Samah El-Ghamrasni; Kevin N Kirouac; Mathilde J Exertier; Zi Jian Xiong; Gilbert G Privé; Calogera M Simonaro; Josefina Casas; Gemma Fabrias; Edward H Schuchman; Patricia V Turner; Razqallah Hakem; Thierry Levade; Jeffrey A Medin
Journal:  EMBO Mol Med       Date:  2013-05-16       Impact factor: 12.137

4.  Acid Sphingomyelinase Deficiency Ameliorates Farber Disease.

Authors:  Nadine Beckmann; Katrin Anne Becker; Stephanie Kadow; Fabian Schumacher; Melanie Kramer; Claudine Kühn; Walter J Schulz-Schaeffer; Michael J Edwards; Burkhard Kleuser; Erich Gulbins; Alexander Carpinteiro
Journal:  Int J Mol Sci       Date:  2019-12-11       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.